Basic HTML Version
125
SCIENTIFIC REPORT 2012
Title:
Randomized multicenter, double-blind, double-masked, group study
placebo-controlled trials on the efficacy and safety of treatment
complementary with mepolizumab, in subjects with severe uncontrolled asthma, refractory to
treatment.
District Attorney:
Glaxosmithkline SA
Principal Investigator:
Christian Domingo Ribas.
Title:
Progressive dose reduction protocol for omalizumab in patients with allergic asthma
corticodepenent; Free IgE as a predictive factor.
District Attorney:
FIS
Principal Investigator:
Christian Domingo Ribas.
Title:
Multicenter clinical trial, phase I, open to study pharmacokinetics, safety and
tolerability of POL7080 administered as a single intravenous infusion in
patients with mechanical ventilation in intensive care units.
District Attorney:
Portola Pharmaceuticals, Inc.
Principal Investigator:
Ignacio Martín-Loeches Carrondo.
Title:
Study of clinical results to compare the effect of fluticasone furoate / vilanterol
inhaled powder, 100/25 µg with placebo on the survival of subjects with disease
Chronic obstructive pulmonary disease (COPD) moderate and with a history or high risk of
cardiovascular disease.
District Attorney:
GlaxoSmithKline Research & Development Limited.
Principal Investigator:
Eduard Monsó Molas.
Title:
International cross-sectional and longitudinal evaluation on asthma control (LIAISON)
District Attorney:
Chiesi Farmaceutici SpA
Principal Investigator:
Eduard Monsó Molas.
Title:
Observational study on the characterization of the symptoms of patients with
chronic obstructive pulmonary disease over 24 hours (ASSES Study).
District Attorney:
Admiral Prodesfarma.
Principal Investigator:
Eduard Monsó Molas.